Corcept Therapeutics (NASDAQ: CORT) reported Q3 EPS of $0.31, $0.11 better than the analyst estimate of $0.20. Revenue for the quarter came in at $81.5 million versus the consensus estimate of $78 million.

For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.